

- Canellos GP, Rosenberg SA, Friedberg JW, et al. Treatment of Hodgkin lymphoma: a 50-year perspective. *J Clin Oncol* 2014;32:163–168.
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013;63:11–30.
- Re D, Thomas RK, Behringer K, et al. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. *Blood* 2005;105:4553–4560.
- Jackson H Jr, Parker F Jr. Hodgkin's disease. *N Engl J Med* 1944;230:1–8.
- Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. *Cancer Res* 1966;26:1063–1083.
- Kuppers R, Rajewsky K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. *Annu Rev Immunol* 1998;16:471–493.
- Kuppers R. The biology of Hodgkin's lymphoma. *Nat Rev Cancer* 2009;9:15–27.
- Re D, Kuppers R, Diehl V. Molecular pathogenesis of Hodgkin's lymphoma. *J Clin Oncol* 2005;23:6379–6386.
- Kuppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. *Proc Natl Acad Sci U S A* 1994;91:10962–10966.
- Eberle FC, Mani H, Jaffe ES. Histopathology of Hodgkin's lymphoma. *Cancer J*. 2009;15:129–137.
- Smith LB. Nodular lymphocyte predominant Hodgkin lymphoma: diagnostic pearls and pitfalls. *Arch Pathol Lab Med* 2010;134:1434–1439.
- Carbone A, Ghoghini A. "Intrafollicular neoplasia" of nodular lymphocyte predominant Hodgkin lymphoma: description of a hypothetical early step of the disease. *Hum Pathol* 2012;43:619–628.
- Falini B, Bigerna B, Pasqualucci L, et al. Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease. *Blood* 1996;87:465–471.
- Carbone A, Ghoghini A, Gattei V, et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. *Blood* 1995;85:780–789.
- Mason DY, Banks PM, Chan J, et al. Nodular lymphocyte predominance Hodgkin's disease. A distinct clinicopathological entity. *Am J Surg Pathol* 1994;18:526–530.
- Brune V, Tiacci E, Pfeil I, et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. *J Exp Med* 2008;205:2251–2268.
- Schwering I, Brauningner A, Klein U, et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. *Blood* 2003;101:1505–1512.
- Stein H, Marafioti T, Foss HD, et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. *Blood* 2001;97:496–501.
- Stein H, Bob R. Is Hodgkin lymphoma just another B-cell lymphoma? *Curr Hematol Malig Rep* 2009;4:125–128.
- Aldinucci D, Rapana B, Olivo K, et al. IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma. *Br J Haematol* 2010;148:115–118.
- Zheng B, Fiumara P, Li YV, et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. *Blood* 2003;102:1019–1027.
- Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. *Blood* 1994;84:1361–1392.
- Younes A, Carbone A. Clinicopathologic and molecular features of Hodgkin's lymphoma. *Cancer Biol Ther* 2003;2:500–507.
- Carbone A, Ghoghini A, Aldinucci D, et al. Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. *Br J Haematol* 2002;117:366–372.
- Carbone A, Ghoghini A, Cabras A, et al. The Germinal centre-derived lymphomas seen through their cellular microenvironment. *Br J Haematol* 2009;145:468–480.
- Fan Z, Natkunam Y, Bair E, et al. Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation. *Am J Surg Pathol* 2003;27:1346–1356.
- Carbone A, Ghoghini A. Nodular lymphocyte predominant Hodgkin lymphoma may show a nodular pattern in which tumour cells do not invade the surrounding spaces. *Br J Haematol* 2013;163:537–538.
- Carbone A, Spina M, Ghoghini A, et al. Nodular lymphocyte predominant Hodgkin lymphoma with non-invasive or early invasive growth pattern suggests an early step of the disease with a highly favorable outcome. *Am J Hematol* 2013;88:161–162.
- Aldinucci D, Ghoghini A, Pinto A, et al. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. *J Pathol* 2010;221:248–263.
- Poppema S, van den Berg A. Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas. *Semin Cancer Biol* 2000;10:345–350.
- Carbone A, Ghoghini A, Gruss HJ, et al. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. *Am J Pathol* 1995;147:912–922.
- Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. *N Engl J Med* 2010;362:875–885.
- Ma Y, Visser L, Roelofsen H, et al. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. *Blood* 2008;111:2339–2346.
- Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. *Blood* 2002;99:4283–4297.
- Carbone A, Ghoghini A, Serrano D, et al. HIV-associated Hodgkin lymphoma. *Curr Opin HIV AIDS* 2009;4:3–10.
- Aldinucci D, Ghoghini A, Pinto A, et al. The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment. *Leuk Lymphoma* 2012;53:195–201.
- Meckes DG Jr, Shair KH, Marquitz AR, et al. Human tumor virus utilizes exosomes for intercellular communication. *Proc Natl Acad Sci U S A* 2010;107:20370–20375.
- Meckes DG Jr, Gunawardena HP, Dekroon RM, et al. Modulation of B-cell exosome proteins by gamma herpesvirus infection. *Proc Natl Acad Sci U S A* 2013;110:E2925–2933.
- Carbone A, Ghoghini A, Aiello A, et al. B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology. *Hum Pathol* 2010;41:621–631.
- Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. *J Exp Med* 2003;198:851–862.
- Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. *Blood* 2003;102:3871–3879.
- Gualco G, Natkunam Y, Bacchi CE. The spectrum of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a description of 10 cases. *Mod Pathol* 2012;25:661–674.
- Tirelli U, Errante D, Dolcetti R, et al. Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. *J Clin Oncol* 1995;13:1758–1767.
- Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. *Blood* 2006;108:3786–3791.
- Ghoghini A, Carbone A. Why would the incidence of HIV-associated Hodgkin lymphoma increase in the setting of improved immunity? *Int J Cancer* 2007;120:2753–2754.
- Deeken JF, Tjen ALA, Rudek MA, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. *Clin Infect Dis* 2012;55:1228–1235.
- Engels EA. Non-AIDS-defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities. *AIDS* 2009;23:875–885.
- Novak RM, Richardson JT, Buchacz K, et al. Immune reconstitution inflammatory syndrome: incidence and implications for mortality. *AIDS* 2012;26:721–730.
- Rajasuriar R, Khoury G, Kamarulzaman A, et al. Persistent immune activation in chronic HIV infection: do any interventions work? *AIDS* 2013;27:1199–1208.
- Kowalkowski MA, Mims MP, Amiran ES, et al. Effect of immune reconstitution on the incidence of HIV-related Hodgkin lymphoma. *PLoS One* 2013;8:e77409.
- Rosenberg SA, Kaplan HS. Evidence for an orderly progression in the spread of Hodgkin's disease. *Cancer Res* 1966;26:1225–1231.
- Gilbert R. Radiotherapy in Hodgkin's disease (malignant granulomatosis): anatomic and clinical foundations; governing principles; results. *Am J Roentgenol Radium Ther Nucl Med* 1939;41:198–241.
- Peters MV. A study of survivals in Hodgkin's disease treated radiologically. *Am J Roentgenol Radium Ther Nucl Med* 1950;63:299–311.
- Kaplan HS. Clinical evaluation and radiotherapeutic management of Hodgkin's disease and the malignant lymphomas. *N Engl J Med* 1968;278:892–899.
- Bowers DC, McNeil DE, Liu Y, et al. Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study. *J Clin Oncol* 2005;23:6508–6515.
- Franklin J, Phuetschow A, Paus M, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. *Ann Oncol* 2006;17:1749–1760.
- Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. *JAMA* 1993;270:1949–1955.
- Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. *BMJ* 2009;339:b4606.
- Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. *J Natl Cancer Inst* 2005;97:1428–1437.
- Swerdlow AJ, Cooke R, Bates A, et al. Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study. *J Clin Oncol* 2012;30:2745–2752.

61. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. *J Clin Oncol* 2003;21:3601–3608.
62. Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. *J Clin Oncol* 2006;24:3128–3135.
63. Girinsky T, Specht L, Ghalibafian M, et al. The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. *Radiation Oncol* 2008;88:202–210.
64. Campbell BA, Voss N, Pickles T, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. *J Clin Oncol* 2008;26:5170–5174.
65. Paumier A, Ghalibafian M, Beaudre A, et al. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. *Int J Radiat Oncol Biol Phys* 2011;80:199–205.
66. Bonadonna G, Bonfante V, Viviani S, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. *J Clin Oncol* 2004;22:2835–2841.
67. Hoskin PJ, Smith P, Maughan TS, et al. Long-term results of a randomised trial of involved field radiotherapy vs extended field radiotherapy in stage I and II Hodgkin lymphoma. *Clin Oncol* 2005;17:47–53.
68. Sasse S, Klimm B, Gorgen H, et al. Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma. *Ann Oncol* 2012;23:2953–2959.
69. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. *N Engl J Med* 2010;363:640–652.
70. Fermé C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. *N Engl J Med*. 2007;357(19):1916–1927.
71. Eich HT, Diehl V, Gørgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. *J Clin Oncol* 2010;28:4199–4206.
72. Canellos GP, Abramson JS, Fisher DC, et al. Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy. *J Clin Oncol* 2010;28:1611–1615.
73. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. *Blood* 2004;104:3483–3489.
74. Wolden SL, Chen L, Kelly KM, et al. Long-term results of CCC 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma—a report from the Children's Oncology Group. *J Clin Oncol* 2012;30:3174–3180.
75. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. *J Clin Oncol* 2005;23:4634–4642.
76. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. *N Engl J Med* 2012;366:399–408.
77. Hay AE, Klimm B, Chen BE, et al. An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. *Ann Oncol* 2013;24:3065–3069.
78. Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. *Eur J Nucl Med Mol Imaging* 2010;37:1824–1833.
79. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. *Blood* 2006;107:52–59.
80. Radford J, Barrington S, Counsell N, et al. Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a 'negative' PET scan after 3 cycles ABVD. Results of the UK NCRI RAPID Trial. *ASH Annual Meeting Abstracts* 2012;120:a547.
81. Andre M, Reman O, Federico M, et al. Interim analysis of the randomized EORTC/LYSA/FIL intergroup H10 trial on early PET-scan driven treatment adaptation in stage I/II Hodgkin lymphoma. *ASH Annual Meeting Abstracts* 2012;120:a549.
82. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. *N Engl J Med* 1998;339:1506–1514.
83. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. *J Clin Oncol* 2003;21:607–614.
84. Guisado-Vasco P, Aranz-Saez R, Canales M, et al. Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series. *Leuk Lymphoma* 2012;53:812–819.
85. Moccia AA, Donaldson J, Chhanabhai M, et al. International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. *J Clin Oncol* 2012;30:3383–3388.
86. Gobbi PG, Ghirardelli ML, Solcia M, et al. Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance. *J Clin Oncol* 2001;19:1388–1394.
87. Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, et al. Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites. *Eur J Haematol* 2001;67:279–288.
88. Scott DW, Chan FC, Hong F, et al. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. *J Clin Oncol* 2013;31:692–700.
89. Sarris AH, Kliche KO, Pethambaram P, et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. *Ann Oncol* 1999;10:433–440.
90. Vassilakopoulos TP, Nadali G, Angelopoulou MK, et al. Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. *Haematologica* 2001;86:274–281.
91. Visco C, Nadali G, Vassilakopoulos TP, et al. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. *Eur J Haematol* 2006;77:387–394.
92. Casanovas RO, Mounier N, Brice P, et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. *J Clin Oncol* 2007;25:1732–1740.
93. Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. *Blood* 2002;100:3935–3941.
94. Sanchez-Espiridon B, Montalban C, Lopez A, et al. A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. *Blood* 2010;116:e12–e17.
95. Chetaille B, Bertucci F, Finetti P, et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. *Blood* 2009;113:2765–2775.
96. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. *N Engl J Med* 2010;362:875–885.
97. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. *J Clin Oncol* 2011;29:1812–1826.
98. Sauer M, Plutschow A, Jachimowicz RD, et al. Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. *Am J Hematol* 2013;88:113–115.
99. His ED. Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment. *Leuk Lymphoma* 2008;49:1668–1680.
100. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. *Blood* 2006;107:52–59.
101. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. *J Clin Oncol* 2007;25:3746–3752.
102. Cerci JJ, Pracchia LF, Linardi CC, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. *J Nucl Med* 2010;51:1337–1343.
103. Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. *J Clin Oncol* 1986;4:1295–1306.
104. Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. *Ann Intern Med* 1986;104:739–746.
105. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. *N Engl J Med* 1992;327:1478–1484.
106. Viviani S, Bonadonna G, Santoro A, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. *J Clin Oncol* 1996;14:1421–1430.
107. Connors JM, Klimo P, Adams G, et al. Treatment of advanced Hodgkin's disease with chemotherapy—comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. *J Clin Oncol* 1997;15:1638–1645.
108. Bartlett NL, Rosenberg SA, Hoppe RT, et al. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. *J Clin Oncol* 1995;13:1080–1088.
109. Horning SJ, Williams J, Bartlett NL, et al. Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. *J Clin Oncol* 2000;18:972–980.
110. Chisesi T, Bellei M, Luminari S, et al. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi. *J Clin Oncol* 2011;29:4227–4233.

111. Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. *J Clin Oncol* 2009;27:5390–5396.
112. Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). *J Clin Oncol* 2013;31:684–691.
113. Diehl V, Sieber M, Ruffer U, et al. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. *Ann Oncol* 1997;8:143–148.
114. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. *N Engl J Med* 2003;348:2386–2395.
115. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSC HD9 study. *J Clin Oncol* 2009;27:4548–4554.
116. Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. *J Clin Oncol* 2009;27:805–811.
117. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. *Lancet* 2012;379:1791–1799.
118. Carde PP, Karrasch M, Fortpied C, et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. *ASCO Meeting Abstracts* 2012;30:8002.
119. Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. *N Engl J Med* 2011;365:203–212.
120. Connors JM. Hodgkin's lymphoma—the great teacher. *N Engl J Med* 2011;365:264–265.
121. Tam CS, Herschtal A, Seymour JF. ABVD versus BEACOPP for Hodgkin's lymphoma. *N Engl J Med* 2011;365:1544–1545.
122. Skoetz N, Trelle S, Rancea M, et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. *Lancet Oncol* 2013;14:943–952.
123. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. *J Clin Oncol* 2009;27:1906–1914.
124. Advani R, Maeda L, Lavori P, et al. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. *J Clin Oncol* 2007;25:3902–3907.
125. Markova J, Kahraman D, Kobe C, et al. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. *Leuk Lymphoma* 2012;53:64–70.
126. Avigdor A, Bulvik S, Levi I, et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma. *Ann Oncol* 2010;21:126–132.
127. Gallamini A, Patti C, Viviani S, et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. *Br J Haematol* 2011;152:551–560.
128. Gallamini A, Rossi A, Patti C, et al. Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses – First Interim Analysis of the GITHL/FIL HD0607 Clinical Trial. *Blood* 2012;120:550.
129. Aleman BM, Raemaekers JM, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. *N Engl J Med* 2003;348:2396–2406.
130. Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. *Lancet Oncol* 2013;14:1348–1356.
131. Borchmann P, Eichenauer DA, Plütschow A, et al. Targeted beacopp variants in patients with newly diagnosed advanced stage classical hodgkin lymphoma: interim results of a randomized phase II study. *Blood* 2013; Abstr# 4344.
132. Kasamon YL, Jacene HA, Gocke CD, et al. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. *Blood* 2012;119:4129–4132.
133. Younes A, Oki Y, McLaughlin P, et al. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. *Blood* 2012;119:4123–4128.
134. Böll B, Plütschow A, Fuchs M, et al. German Hodgkin Study Group Phase I trial of doxorubicin, vinblastine, dacarbazine, and lenalidomide (AVD-RV) for older Hodgkin lymphoma patients. *Blood* 2013; Abstr# 3054.
135. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. *J Clin Oncol* 2002;20:2101–2108.
136. Boll B, Gorgen H, Fuchs M, et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. *J Clin Oncol* 2013;31:1522–1529.
137. Wongso D, Fuchs M, Plütschow A, et al. Treatment-related mortality in patients with advanced-stage Hodgkin lymphoma: an analysis of the German Hodgkin Study Group. *J Clin Oncol* 2013;31:2819–2824.
138. Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. *J Clin Oncol* 2005;23:7614–7620.
139. Cote GM, Canellos GP. Can low-risk, early-stage patients with Hodgkin lymphoma be spared radiotherapy? *Curr Hematol Malig Rep* 2011;6:180–186.
140. Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. *J Clin Oncol* 2003;21:4386–4394.
141. Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. *J Clin Oncol* 2007;25:1489–1497.
142. Franklin J, Plütschow A, Paus M, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. *Ann Oncol* 2006;17:1749–1760.
143. Baxi SS, Matasar MJ. State-of-the-art issues in Hodgkin's lymphoma survivorship. *Curr Oncol Rep* 2010;12:366–373.
144. Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. *J Natl Cancer Inst* 2005;97:1428–1437.
145. Scholz M, Engert A, Franklin J, et al. Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL—experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis. *Ann Oncol* 2011;22:681–688.
146. Behringer K, Breuer K, Reineke T, et al. Secondary amenorrhoea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. *J Clin Oncol* 2005;23:7555–7564.
147. Sieniawski M, Reineke T, Josting A, et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSC) clinical trials. *Ann Oncol* 2008;19:1795–1801.
148. Hodgson DC, Pintilie M, Gitterman L, et al. Fertility among female Hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. *Hematol Oncol* 2007;25:11–15.
149. Kulkarni SS, Sastry PS, Saikia TK, et al. Gonadal function following ABVD therapy for Hodgkin's disease. *Am J Clin Oncol* 1997;20:354–357.
150. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. *J Natl Cancer Inst* 2007;99:206–214.
151. Evens AM, Hong F, Gordon LI, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. *Br J Haematol* 2013;161:76–86.
152. Evens AM, Sweetenham JW, Horning SJ. Hodgkin lymphoma in older patients: an uncommon disease in need of study. *Oncology* 2008;22:1369–1379.
153. Gobbi PG, Federico M. What has happened to VBM (vinblastine, bleomycin, and methotrexate) chemotherapy for early-stage Hodgkin lymphoma? *Crit Rev Oncol Hematol* 2012;82:18–24.
154. Levis A, Anselmo AP, Ambrosetti A, et al. VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. *Ann Oncol* 2004;15:123–128.
155. Proctor SJ, Wilkinson J, Jones G, et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. *Blood* 2012;119:6005–6015.
156. Pereg D, Koren C, Lishner M. The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancy. *Haematologica* 2007;92:1230–1237.
157. Woo SY, Fuller LM, Cundiff JH, et al. Radiotherapy during pregnancy for clinical stages IA-IIA Hodgkin's disease. *Int J Radiat Oncol Biol Phys* 1992;23:407–412.
158. Yahalom J. Treatment options for Hodgkin's disease during pregnancy. *Leuk Lymphoma* 1990;2:151.
159. Connors JM. Challenging problems: coincident pregnancy, HIV infection, and older age. *Hematology Am Soc Hematol Educ Program* 2008: 334–339.
160. Kal HB, Struikmans H. Radiotherapy during pregnancy: fact and fiction. *Lancet Oncol* 2005;6:328–333.
161. Rizaack T, Mega A, Legare R, et al. Management of hematological malignancies during pregnancy. *Am J Hematol* 2009;84:830–841.
162. Lazarus HM, Rowlings PA, Zhang MJ, et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. *J Clin Oncol* 1999;17:534–545.
163. André M, Henry-Amar M, Pico JL, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. *J Clin Oncol* 1999;17:222.
164. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. *Lancet* 1993;341:1051–1054.

165. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. *Lancet* 2002;359:2065–2071.
166. Josting A, Rueffer U, Franklin J, et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. *Blood* 2000;96:1280–1286.
167. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. *J Clin Oncol* 2002;20:221–230.
168. Pfreundschuh MG, Rueffer U, Lathan B, et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. *J Clin Oncol* 1994;12:580–586.
169. Colwill R, Crump M, Couture F, et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. *J Clin Oncol* 1995;13:396–402.
170. Martin A, Fernandez-Jimenez JC, Caballero MD, et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. *Br J Haematol* 2001;113:161–171.
171. Rodriguez J, Rodriguez MA, Fayad L, et al. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. *Blood* 1999;93:3632–3636.
172. Ribrag V, Nasr F, Bouhris JH, et al. VIP (etoposide, ifosfamide and cisplatin) as a salvage intensification program in relapsed or refractory Hodgkin's disease. *Bone Marrow Transplant* 1998;21:969–974.
173. Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. *Ann Oncol* 2002;13:1628–1635.
174. Baetz T, Belch A, Couban S, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. *Ann Oncol* 2003;14:1762–1767.
175. Chau I, Harries M, Cunningham D, et al. Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. *Br J Haematol* 2003;120:970–977.
176. Ferme C, Mounier N, Divine M, et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. *J Clin Oncol* 2002;20:467–475.
177. Proctor SJ, Jackson GH, Lennard A, et al. Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK). *Ann Oncol* 2003;14:i47–i50.
178. Bonfante V, Viviani S, Devizzi L, et al. High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease. *Eur J Haematol Suppl* 2001;64:51–55.
179. Josting A, Müller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. *J Clin Oncol* 2010;28:5074–5080.
180. Kuruvilla J, Nagy T, Pintilie M, et al. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. *Cancer* 2006;106:353–360.
181. Puig N, Pintilie M, Seshadri T, et al. Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma. *Haematologica* 2010;95:1496–1502.
182. Moskowitz CH, Kewalramani T, Nimer SD, et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. *Br J Haematol* 2004;124:645–652.
183. Akhtar S, El Weshi A, Abdelsalam M, et al. Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients. *Bone Marrow Transplant* 2007;40:651–658.
184. Cysz J, Szydlo R, Knopinska-Posluszny W, et al. Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy. *Bone Marrow Transplant* 2004;33:1225–1229.
185. Brandwein JM, Callum J, Sutcliffe SB, et al. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease. *Bone Marrow Transplant* 1990;5:99–103.
186. Stewart AK, Brandwein JM, Sutcliffe SB, et al. Mini-beam as Salvage Chemotherapy for Refractory Hodgkin's Disease and Non-Hodgkin's Lymphoma. *Leuk Lymphoma* 1991;5:111–115.
187. Ardeshtna KM, Kakouros N, Qian W, et al. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. *Br J Haematol* 2005;130:363–372.
188. Villa D, Seshadri T, Puig N, et al. Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy. *Haematologica* 2012;97:751–757.
189. Dreger P, Kloss M, Petersen B, et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. *Blood* 1995;86:3970–3978.
190. Watts MJ, Sullivan AM, Jamieson E, et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. *J Clin Oncol* 1997;15:535–546.
191. Weaver CH, Zhen B, Buckner CD. Treatment of patients with malignant lymphoma with Mini-BEAM reduces the yield of CD34+ peripheral blood stem cells. *Bone Marrow Transplant* 1998;21:1169–1170.
192. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. *Blood* 2001;97:616–623.
193. Jabbour E, Hosing C, Ayers G, et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. *Cancer* 2007;109:2481–2489.
194. Moskowitz AJ, Yahalom J, Kewalramani T, et al. Pre-transplant functional imaging predicts outcome following autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma. *Blood* 2010;116:4934–4937.
195. Moskowitz CH, Matar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. *Blood* 2012;119:1665–1670.
196. Crump M, Smith AM, Brandwein J, et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. *J Clin Oncol* 1993;11:704–711.
197. Stewart DA, Guo D, Gluck S, et al. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation. *Bone Marrow Transplant* 2000;26:383–388.
198. Stuart MJ, Chao NS, Horning SJ, et al. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. *Biol Blood Marrow Transplant* 2001;7:552–560.
199. Evens A, Altman J, Mittal B, et al. Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. *Ann Oncol* 2007;18:679–688.
200. Bains T, Chen AI, Lemieux A, et al. Improved outcome with busulfan, melphalan and thiopeta conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma. *Leuk Lymphoma* 2014;55:583–587.
201. Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). *Ann Oncol* 2005;16:116–123.
202. Josting A, Müller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. *J Clin Oncol* 2010;28:5074–5080.
203. Fung HC, Stiff P, Schriber J, et al. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma. *Biol Blood Marrow Transplant* 2007;13:594–600.
204. Morschhauser F, Brice P, Ferme C, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter h96 trial by the GELA/SFGM study group. *J Clin Oncol* 2008;26:5980–5987.
205. Puig N, Pintilie M, Seshadri T, et al. Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma. *Haematologica* 2010;95:1496–1502.
206. Gajewski JL, Phillips CL, Sobocinski KA, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. *J Clin Oncol* 1996;14:572–578.
207. Peniket AJ, Ruiz de Elvira MC, Taghipour C, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. *Bone Marrow Transplant* 2003;31:667–678.
208. Anderson JE, Litzow MR, Appelbaum FR, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. *J Clin Oncol* 1993;11:2342–2350.
209. Akpek C, Ambinder RF, Piantadosi S, et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. *J Clin Oncol* 2001;19:4314–4321.
210. Anderlini P, Acholonu SA, Okoroji GJ, et al. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. *Bone Marrow Transplant* 2004;34:511–514.

211. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. *Lancet* 2005;365:1934–1941.
212. Peggs KS, Sureda A, Qian W, et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. *Br J Haematol* 2007;139:70–80.
213. Alvarez I, Sureda A, Caballero MD, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. *Biol Blood Marrow Transplant* 2006;12:172–183.
214. Burroughs LM, O'Donnell PV, Sandmaier BM, et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. *Haematologica* 2008;93:257–264.
215. Burroughs LM, O'Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. *Biol Blood Marrow Transplant* 2008;14:1279–1287.
216. Marcel PD, Parameswaran NH, Jeanette C, et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. *Biol Blood Marrow Transplant* 2009;15:109–117.
217. Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. *J Clin Oncol* 2008;26:455–462.
218. Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. *Haematologica* 2012;97:310–317.
219. Anderlini P, Saliba R, Acholonu S, et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. *Haematologica* 2008;93:257–264.
220. Devetten MP, Hari PN, Carreras J, et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. *Biol Blood Marrow Transplant* 2009;15:109–117.
221. Brunstein CG, Cantero S, Cao Q, et al. Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation. *Biol Blood Marrow Transplant* 2009;15:214–222.
222. Rodrigues CA, Sanz G, Brunstein CG, et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. *J Clin Oncol* 2009;27:256–263.
223. Thomson KJ, Peggs KS, Smith P, et al. Improved outcome following reduced intensity allogeneic transplantation in Hodgkin's lymphoma relapsing post-autologous transplantation. *Blood* 2005;106:abstract 657.
224. Castagna L, Sarina B, Todisco E, et al. Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma. *Biol Blood Marrow Transplant* 2009;15:432–438.
225. Smith SM, van Besien K, Carreras J, et al. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. *Biol Blood Marrow Transplant* 2008;14:904–912.
226. Arai S, Fanale M, Devos S, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplantation. *Leuk Lymphoma* 2013;54:2531–2533.
227. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. *N Engl J Med* 2010;363:1812–1821.
228. Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. *Clin Cancer Res* 2012;18:248–255.
229. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. *J Clin Oncol* 2012;30:2183–2189.
230. Buglio D, Georgakis GV, Hanabuchi S, et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. *Blood* 2008;112:1424–1433.
231. Buglio D, Mamidipudi V, Khaskhely NM, et al. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism. *Br J Haematol* 2010;151:387–396.
232. Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. *Nat Immunol* 2007;8:239–245.
233. Kirschbaum MH, Goldman BH, Zain JM, et al. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. *Leuk Lymphoma* 2012;53:259–262.
234. Zhou N, Moradei O, Raeppl S, et al. Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. *J Med Chem* 2008;51:4072–4075.
235. Fournel M, Bonfils C, Hou Y, et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. *Mol Cancer Ther* 2008;7:759–768.
236. Younes A, Oki Y, Bociek RG, et al. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. *Lancet Oncol* 2011;12:1222–1228.
237. Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. *J Clin Oncol* 2012;30:2197–2203.
238. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. *Nat Rev Cancer* 2009;9:550–562.
239. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. *Oncogene* 2008;27:5497–5510.
240. Hennessy BT, Smith DL, Ram PT, et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. *Nat Rev Drug Discov* 2005;4:988–1004.
241. Meadows SA, Vega F, Kashishian A, et al. PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. *Blood* 2012;119:1897–1900.
242. Johnston PB, Pinter-Brown L, Rogerio J, et al. Everolimus for relapsed/refractory classical Hodgkin lymphoma: multicenter, open-label, single-arm, phase 2 study. *54th ASH Annual Meeting* 2012;Abstract 2740.
243. von Tresckow B, Plitischow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. *J Clin Oncol* 2012;30:907–913.
244. Levis A, Anselmo AP, Ambrosetti A, et al. VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. *Ann Oncol* 2004;15:123–128.
245. Gobbi PG, Federico M. What has happened to VBM (vinblastine, bleomycin, and methotrexate) chemotherapy for early-stage Hodgkin lymphoma? *Crit Rev Oncol Hematol* 2012;82:18–24.
246. Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. *Ann Oncol* 2007;18:1071–1079.
247. Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. *Haematologica* 2007;92:35–41.
248. Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. *Ann Oncol* 2002;13:1628–1635.
249. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. *J Clin Oncol* 1999;17:3776–3785.
250. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. *Lancet* 2002;359:2065–2071.
251. Proctor SJ, Jackson GH, Lennard A, et al. Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK). *Ann Oncol* 2003;14:i47–i50.